Search for Terms or Answers
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
For someone who has spent so much of his career recognizing the work of others, it is fitting that Dr. John J. “Jack” Cush should have his own moment in the spotlight.
As the leaves start changing color and spooky decorations populate neighborhood doorsteps, another autumnal tradition begins: vaccination counseling. Fall offers a golden opportunity to protect our patients before respiratory viruses fill our waiting rooms. In patients with rheumatologic
Dr. Jack Cush reviews this week's news from RheumNow.com, including: placebo trumps controversial therapies, the dynamics of disease activity, fuse the big toe, and patients don’t appreciate being told “it's all in your head”!
There's this low grade buzz from some rheumatologists about the potential analgesic benefits of low dose naltrexone. I haven't used it. Should you?
In honor of World Arthritis Day (Oct. 12th), The Lancet has published a public Health Policy report is to "outline a globally relevant roadmap to address the osteoarthritis identity problem, focusing on health policy responses."
Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), appeared strongly effective in an Italian registry study -- a step, maybe, toward setting to rest questions about its efficacy, if not its safety.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
